Montrusco Bolton Investments Inc. Purchases 165,188 Shares of IDEXX Laboratories, Inc. $IDXX

Montrusco Bolton Investments Inc. raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 93.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 342,120 shares of the company’s stock after acquiring an additional 165,188 shares during the period. IDEXX Laboratories makes up 2.8% of Montrusco Bolton Investments Inc.’s portfolio, making the stock its 14th biggest holding. Montrusco Bolton Investments Inc. owned approximately 0.43% of IDEXX Laboratories worth $186,707,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Harbour Investments Inc. raised its stake in IDEXX Laboratories by 13.3% during the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares during the last quarter. CWA Asset Management Group LLC increased its holdings in shares of IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after purchasing an additional 17 shares during the period. Rockland Trust Co. increased its holdings in shares of IDEXX Laboratories by 4.4% during the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the period. Prime Capital Investment Advisors LLC raised its position in shares of IDEXX Laboratories by 0.5% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after buying an additional 18 shares during the last quarter. Finally, Pinnacle Associates Ltd. raised its position in shares of IDEXX Laboratories by 1.5% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after buying an additional 18 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent research reports. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $557.80 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.00 billion, a P/E ratio of 41.08, a PEG ratio of 3.05 and a beta of 1.55. The company’s 50-day simple moving average is $555.31 and its 200 day simple moving average is $609.16.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $2.91 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.